JP2009529576A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529576A5
JP2009529576A5 JP2009500402A JP2009500402A JP2009529576A5 JP 2009529576 A5 JP2009529576 A5 JP 2009529576A5 JP 2009500402 A JP2009500402 A JP 2009500402A JP 2009500402 A JP2009500402 A JP 2009500402A JP 2009529576 A5 JP2009529576 A5 JP 2009529576A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
virus
composition according
highly conserved
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009500402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529576A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/006113 external-priority patent/WO2007106404A2/en
Publication of JP2009529576A publication Critical patent/JP2009529576A/ja
Publication of JP2009529576A5 publication Critical patent/JP2009529576A5/ja
Pending legal-status Critical Current

Links

Images

JP2009500402A 2006-03-10 2007-03-09 持続感染または潜伏感染を引き起こすウイルスに対するワクチン Pending JP2009529576A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78112306P 2006-03-10 2006-03-10
PCT/US2007/006113 WO2007106404A2 (en) 2006-03-10 2007-03-09 Vaccine for viruses that cause persistent or latent infections

Publications (2)

Publication Number Publication Date
JP2009529576A JP2009529576A (ja) 2009-08-20
JP2009529576A5 true JP2009529576A5 (https=) 2010-04-30

Family

ID=38510006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009500402A Pending JP2009529576A (ja) 2006-03-10 2007-03-09 持続感染または潜伏感染を引き起こすウイルスに対するワクチン

Country Status (5)

Country Link
US (1) US8501194B2 (https=)
EP (1) EP2001516A4 (https=)
JP (1) JP2009529576A (https=)
CA (1) CA2645507A1 (https=)
WO (1) WO2007106404A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009037359A1 (en) * 2007-09-21 2009-03-26 Sanofi Pasteur Vaccine composition for the prevention of cmv infections
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US8979890B2 (en) 2010-10-01 2015-03-17 Ethicon Endo-Surgery, Inc. Surgical instrument with jaw member
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
EA033467B1 (ru) * 2011-01-31 2019-10-31 Univ Pennsylvania Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
EP2726097A4 (en) * 2011-07-01 2015-03-11 Univ California HERPES VIRUS VACCINE AND METHOD OF USE
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
EP3246400B1 (en) * 2012-01-09 2019-10-23 Sanofi Pasteur Biologics, LLC Purification of herpes virus
EP2852662B1 (en) 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesvirus compositions and related methods
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
CA2890061A1 (en) * 2012-12-04 2014-06-12 Merck Sharp & Dohme Corp. Conditional replicating viral vectors
MX384992B (es) 2014-06-13 2025-03-14 Glaxosmithkline Biologicals Sa Combinaciones inmunógenas.
US10314383B2 (en) 2015-03-30 2019-06-11 Gary McClellan Thompson Wearable sports equipment carrier with personal flotation device
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
CN111032681B (zh) * 2017-08-30 2024-05-17 Km生物医薬股份公司 修饰型HSV gB蛋白及包含其的HSV疫苗
MA53158A (fr) * 2018-07-20 2021-05-26 Aicuris Gmbh & Co Kg Procédés de criblage et d'identification d'agents inhibant ou modulant le complexe de sortie nucléaire du virus de l'herpès
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CA3230564A1 (en) * 2021-09-13 2023-03-16 Jean-Pol DETIFFE Method to generate personalized neoantigens of a tumor of a patient
EP4147712A1 (en) * 2021-09-13 2023-03-15 OncoDNA Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient
US20250319132A1 (en) * 2024-04-16 2025-10-16 Mirror Biologics, Inc. Methods and compositions for improving the immune response against viral pathogens

Similar Documents

Publication Publication Date Title
JP2009529576A5 (https=)
Del Val et al. Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89
CN112618707B (zh) 一种SARS-CoV-2冠状病毒疫苗及其制备方法
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
JP7579245B2 (ja) 組成物及び方法
KR101702956B1 (ko) 다수의 상동성 뉴클레오티드 서열을 포함하는 벡터
CN113201507B (zh) 一种重组的伪狂犬病病毒及其疫苗组合物
CN104271745A (zh) 用于治疗巨细胞病毒的组合物和方法
PT2753364T (pt) Citomegalovirus de replicação condicional como uma vacina para cmv
CN109415705A (zh) 组合初免:加强免疫疗法
CN116457461A (zh) 重组hvt及其用途
CN115845042A (zh) 重组新型冠状病毒s蛋白三聚体疫苗组合物及其应用
Stock et al. CTL response compensation for the loss of an immunodominant class I‐restricted HSV‐1 determinant
CN111154778B (zh) 禽新城疫病毒新型基因工程亚单位疫苗
WO2023236822A1 (zh) H5n6禽流感广谱性疫苗的开发及其应用
CN114276969A (zh) 一种SARS-CoV-2细菌样颗粒及其在疫苗中的应用
US20220257748A1 (en) Hepatitis b virus-specific t cell responses
CN121752290A (zh) Dev作载体的禽流感h9疫苗
EP1624890A2 (en) Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes
WO2023207717A1 (zh) H5n8禽流感广谱性疫苗的开发及其应用
CN116549627A (zh) 基于腺病毒载体的广谱新冠疫苗及其应用
WO2023092023A2 (en) Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19)
CN113248576A (zh) 一种针对冠状病毒的核酸疫苗及其制备方法
Li et al. Construction and anti-tumor effects of recombinant fowlpox virus expressing Newcastle disease virus hemagglutinin-neuramidinase gene
CN113308440B (zh) 一种n7-甲基转移酶缺陷型冠状病毒减毒疫苗株及其制备方法与应用